Self-collection and extended genotyping advance cervical cancer screening

In a recent interview with Contemporary OB/GYN, Jeff Andrews, MD, FRCSC, vice president of Medical Affairs at BD Life Sciences, discussed advancements and challenges in cervical cancer screening.

Andrews highlighted new screening options aimed at improving accessibility. One key innovation is FDA-approved self-collection in health care settings, typically done privately, such as in bathrooms at clinics or labs. There is ongoing work to introduce self-collection options for at-home use in the United States. Additionally, the American Society for Colposcopy and Cervical Pathology is updating guidelines to incorporate extended genotyping and self-collection methods.

Andrews mentioned that the United States Preventive Services Task Force is revising its cervical cancer screening guidelines, emphasizing primary human papillomavirus (HPV) screening and including self-collection as a recommended approach. While these developments promise increased accessibility, Andrews noted that the United States lacks a national cancer screening program. Instead, cervical cancer screening is "opportunistic," meaning patients must seek it out or rely on their health care providers to initiate the conversation.

Additionally, Andrews stressed the importance of educating women about these advancements. He clarified that cervical screening aims to detect pre-cancerous conditions rather than cancer itself, enabling early treatment and prevention. HPV testing, particularly with extended genotyping, assesses the risk of pre-cancer rather than simply detecting the virus, according to Andrews.

The discussion concluded with Andrews expressing enthusiasm for the progress being made and emphasizing the need for clear communication about the benefits of extended genotyping and self-collection options. These advancements hold potential for increasing awareness, accessibility, and prevention efforts in cervical cancer care.